{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:31:42Z","timestamp":1791189102301,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,12,13]],"date-time":"2010-12-13T00:00:00Z","timestamp":1292198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy and safety of levetiracetam (LEV), administered for management of levodopa\u2010induced dyskinesias (LID) in Parkinson's disease (PD), was examined using a multicenter, double\u2010blind, placebo\u2010controlled, parallel groups, crossover trial. Because of having a period effect, data after crossover point was excluded from analysis. Levodopa\u2010treated PD participants with LID (n = 38) received LEV 500 mg\/day, were assessed, titrated to 1,000 mg\/day and reassessed, before and after crossover. The placebo group followed the same routine. Primary efficacy was defined from percent change in \u201cOn with LID\u201d time from patient diaries. Secondary efficacy assessment used \u201cOn without LID,\u201d \u201cOff\u201d time, unified PD rating scale (UPDRS), clinical global impression (CGI), and Goetz dyskinesia scale after levodopa challenge. Safety measures were also performed. On with LID time decreased 37 minutes (95% confidence interval [CI] 0.59, 7.15; <jats:italic>P<\/jats:italic> = 0.02) at 500 mg\/day, 7.85% 75 minutes (95% CI 3.3, 12.4; <jats:italic>P<\/jats:italic> = 0.002) at 1,000 mg\/day. On without LID time increased by 46 minutes (95% CI \u22121.55, \u22120.03; <jats:italic>P<\/jats:italic> = 0.04) at 500 mg\/day and 55 minutes (95% CI \u221210.39, \u22121.14; <jats:italic>P<\/jats:italic> = 0.018) at 1,000 mg\/day. UPDRS 32 showed decreased dyskinesia duration mean change 0.35 (95% CI 0.09, 0.5; <jats:italic>P<\/jats:italic> = 0.009) at 1,000 mg\/day. CGI showed LID decreased by 0.7 (95% CI 0.21, 1.18; <jats:italic>P<\/jats:italic> = 0.006) at 1,000 mg\/day. Patient diaries and UPDRS show no increase in Off time. This exploratory trial provides evidence that LEV in 1,000 mg\/day, slowly titrated, could be useful in improving LID as was assessed with patient diaries, UPDRS, and CGI scales, safely, with minimal side effects. \u00a9 2010 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.23355","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T09:28:53Z","timestamp":1292318933000},"page":"264-270","source":"Crossref","is-referenced-by-count":52,"title":["Levetiracetam for the management of levodopa\u2010induced dyskinesias in Parkinson's disease"],"prefix":"10.1002","volume":"26","author":[{"given":"P.","family":"Stathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Konitsiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tagaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on Behalf of VALID\u2010PD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,13]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"96","volume-title":"Movement disorders","author":"Marsden CD","year":"1982"},{"key":"e_1_2_7_3_2","first-page":"281","volume-title":"Drug\u2010induced movement disorders","author":"Nutt JC","year":"1992"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150200032"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2005.01096.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110317.52453.6C"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1323"},{"issue":"1","key":"e_1_2_7_8_2","first-page":"S22","article-title":"Pathophysiology of levodopa\u2010induced dyskinesias in Parkinson's disease: problems with the current model","volume":"47","author":"Obeso JA","year":"2000","journal-title":"Ann Neurol"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21475"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2003.11.065"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000135478.70905.3d"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10542"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.11.003"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e318033a6c7"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20563"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000220814.48360.F4"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000157067.50948.2c"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20248"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199907)14:4<572::AID-MDS1005>3.0.CO;2-C"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.6.1227"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0081-z"},{"key":"e_1_2_7_22_2","volume-title":"The Little Handbook of Statistical Practice","author":"Dallal G","year":"2008"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000131893"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20835"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050203"},{"key":"e_1_2_7_26_2","doi-asserted-by":"crossref","unstructured":"BrotchieJM.Nondopaminergic mechanisms in levodopa\u2010induced dyskinesias.2005;20:919\u2013931.","DOI":"10.1002\/mds.20612"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22019"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000242888.30755.5d"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420513"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2005.04179.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.14.4.377"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh102"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721080-00005"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23355","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.23355","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.23355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:59:12Z","timestamp":1760961552000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.23355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,13]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1002\/mds.23355"],"URL":"https:\/\/doi.org\/10.1002\/mds.23355","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,13]]}}}